Real‑World Guidance from Clinicians

Explore our on‑demand webinar videos, featuring a panel of experts sharing clinical experience and evidence.

Real experiences, real patients, real impact.

ACT FAST! Making the most of thrombolysis in Acute Ischaemic Stroke (AIS) patients

This video covers:

Real-World Case Study 1: Early-Presenting Patient

Real-World Case Study 2: Atypical Elderly Patient

Clinical Decision-Making & Thrombolysis Selection

Evidence Review: AcT Study & Safety Outcomes

Evidence Review: EXTEND- IA-TNK study and safety outcomes

Impact of Metalyse 25 mg in Clinical Practice

Conclusion and a takeaway challenge

ACT FAST! Making the most of thrombolysis in acute ischaemic stroke (AIS) patients thumbnail

ACT FAST! Making the most of thrombolysis in AIS patients

Access the summary video of the above main webinar here.

Watch now

How can Metalyse 25 mg increase workflow efficiency in the thrombolytic treatment of AIS patients compared with Actilyse®(alteplase)?

This video covers:

Objectives: Understanding the switch to Metalyse 25 mg from Actilyse

Stroke Treatment Landscape in the UK

Why Switch? Workflow benefits of Metalyse 25 mg vs Actilyse

Evidence Review: AcT & ATTEST-2 Clinical Trials

Real-World Implementation: Experiences from England & Scotland

Impact on Workflow, Governance & Training

How can Metalyse 25 mg increase workflow efficiency in the thrombolytic treatment of acute ischaemic stroke? thumbnail

How can Metalyse 25 mg increase workflow efficiency in the thrombolytic treatment of AIS?

Access the summary video of the above main webinar here.

Watch now

View related resources

Learn more

Learn more

Learn more

Back to Metalyse Homepage

Actilyse is indicated for the fibrinolytic treatment of acute ischaemic stroke. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques (e.g. cranial computerised tomography or other diagnostic imaging method sensitive for the presence of haemorrhage). The treatment effect is time-dependent; therefore earlier treatment increases the probability of a favourable outcome.²

References

Metalyse 25 mg (tenecteplase) Summary of Product Characteristics.
Actilyse (alteplase) Summary of Product Characteristics.

PC-GB-112307 April 2026

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.

Because Every
Minute Matters